NASDAQ:SURF Surface Oncology (SURF) Stock Price, News & Analysis → A letter is coming from the 'Bureau of the Fiscal Service'. (From Stansberry Research) (Ad) Free SURF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.01▼$1.0950-Day Range$0.88▼$1.0852-Week Range$0.56▼$1.43Volume1.51 million shsAverage Volume430,375 shsMarket Capitalization$65.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Surface Oncology alerts: Email Address Ad Porter & CompanyMusk, Bezos, and Gates All On Board… Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.To get all the details of this controversial tech – click here now. About Surface Oncology Stock (NASDAQ:SURF)Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.Read More Ad Porter & CompanyMusk, Bezos, and Gates All On Board… Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.To get all the details of this controversial tech – click here now. SURF Stock News HeadlinesMay 25 at 11:22 AM | msn.comEvolving treatment paradigms in multiple myeloma could improve patient outcomesMay 24 at 3:55 PM | msn.comHPV vaccines can prevent cancer in men as well as women: StudyMay 24 at 3:55 PM | msn.comQ&A: Quadruple therapies and the future of multiple myeloma treatmentMay 24 at 3:55 PM | msn.comScientists uncover new treatment pathway for rare 'spider web' childhood brain tumorsMay 21, 2024 | bizjournals.comFormer Bayer, Genentech exec's biotech raises $225 million to target ulcerative colitisMay 19, 2024 | msn.comInfluencers Are Saying Sunscreen Causes Cancer. They Are Wrong.May 18, 2024 | msn.comUnlocking the body's defenses: Understanding immunotherapyMay 18, 2024 | msn.comHow COVID Vaccines Stand Up to New FLiRT VariantsMay 15, 2024 | forbes.comInnovationRx: Battle Of The AI Medical ScribesMay 13, 2024 | markets.businessinsider.comInnovative T-Cell Therapy Approach: TScan’s Promising Outlook and Buy Rating by Gil BlumMay 13, 2024 | msn.comAEMD: Data From In Vitro Study Supports Advancing Planned Oncology Clinical TrialMay 10, 2024 | msn.comGoT-ChA: New tool reveals how gene mutations affect cellsMay 10, 2024 | msn.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call TranscriptMay 9, 2024 | msn.comNew Labyrinth Debuts At Kin Wellness Center In BuckinghamMay 8, 2024 | msn.comRevolutionary CAR-T cell therapy looks to break through beyond blood cancerMay 8, 2024 | msn.comNew Survey Reveals Alarming Misconceptions About Sunscreen and Sun ExposureMay 6, 2024 | msn.comStudy: These 2 Body Types May Be Linked to an Increased Risk of Developing Colorectal CancerMay 3, 2024 | msn.comNewly discovered mechanism of T-cell control can interfere with cancer immunotherapiesMay 1, 2024 | finance.yahoo.comValar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder CancerMay 1, 2024 | bloomberg.comUK’s FTSE 100 Edges Lower in Thin Trading Ahead of Fed DecisionMay 1, 2024 | msn.comNew technique improves T cell-based immunotherapies for solid tumorsMay 1, 2024 | msn.comIncyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call TranscriptMay 1, 2024 | msn.comScientists Debunk 'Really Dangerous' Online Myths About Sun ProtectionMay 1, 2024 | finance.yahoo.comCD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity InsightMay 1, 2024 | msn.comScientists Debunk 'Really Dangerous' Myths About Sun ProtectionSee More Headlines Receive SURF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SURF CUSIPN/A CIK1718108 Webwww.surfaceoncology.com Phone(617) 714-4096FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,590,000.00 Net MarginsN/A Pretax Margin-211.95% Return on Equity-107.81% Return on Assets-65.57% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$30 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book1.32Miscellaneous Outstanding Shares60,824,000Free Float53,525,000Market Cap$65.08 million OptionableNot Optionable Beta1.75 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMs. Lisa McGrathChief People OfficerMs. Shannon Rourke DevensSr. VP of Devel. OperationsKey CompetitorsAVROBIONASDAQ:AVROAssembly BiosciencesNASDAQ:ASMBBrainstorm Cell TherapeuticsNASDAQ:BCLIvTv TherapeuticsNASDAQ:VTVTLipocineNASDAQ:LPCNView All CompetitorsInsidersJessica FeesSold 9,434 sharesTotal: $8,867.96 ($0.94/share)Robert W RossSold 16,713 sharesTotal: $15,710.22 ($0.94/share)Chandra AdamsSold 3,901 sharesTotal: $3,666.94 ($0.94/share) SURF Stock Analysis - Frequently Asked Questions Should I buy or sell Surface Oncology stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SURF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SURF, but not buy additional shares or sell existing shares. View SURF analyst ratings or view top-rated stocks. How were Surface Oncology's earnings last quarter? Surface Oncology, Inc. (NASDAQ:SURF) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.04. The firm had revenue of $0.39 million for the quarter. What is Jeff Goater's approval rating as Surface Oncology's CEO? 5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Surface Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA). When did Surface Oncology IPO? Surface Oncology (SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO. This page (NASDAQ:SURF) was last updated on 5/26/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s PRIME is Set to Shock the WorldInvestorPlaceJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaNew Options need New Trading StrategiesNetpicks$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surface Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.